Psoriasis Clinical Trial
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.
Full Description
Multi-center, double-blind, randomized, placebo controlled, parallel-group study comparing test and reference products to a placebo control in the treatment of scalp psoriasis
Eligibility Criteria
Inclusion Criteria:
Healthy male or non-pregnant female aged ≥18 years
All male subjects had to agree to use accepted methods of birth control with their partners, from the day of the first application of the study drug to 30 days after the last application of the study drug
Willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits
A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp
Exclusion Criteria:
Female subjects who were pregnant, nursing, or planning to become pregnant during study participation
Known hypersensitivity to calcipotriene, betamethasone dipropionate, other corticosteroids, or to any ingredients in the study drugs
Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative, or pustular psoriasis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Charlotte North Carolina, 28217, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.